Wave Life Sciences financials
$3.64−0.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $38.2M | $17.2M | $7.6M | $8.7M | $9.2M | $83.7M | -$7.7M | $19.7M | $12.5M | $29.1M | $49.2M |
| Gross profit | $2.3M | $38.2M | $17.2M | $7.6M | $8.7M | $9.2M | $83.7M | -$7.7M | $19.7M | $12.5M | $29.1M | $49.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$73.8M | -$31.3M | -$56.5M | -$56.4M | -$52.8M | -$49.8M | $23.0M | -$63.9M | -$35.0M | -$34.5M | -$18.7M | $4.4M |
| Net income | -$69.4M | -$26.1M | -$53.2M | -$53.9M | -$50.5M | -$46.9M | $29.3M | -$61.8M | -$32.9M | -$31.6M | -$16.3M | $7.0M |
| Net margin | −3052.6% | −68.2% | −308.4% | −707.8% | −580.2% | −510.9% | 34.9% | 804.8% | −167.2% | −251.7% | −55.9% | 14.2% |
| Diluted EPS | $-0.34 | $-0.13 | $-0.29 | $-0.32 | $-0.31 | $-0.29 | $0.18 | $-0.47 | $-0.25 | $-0.24 | $-0.15 | $0.07 |
| EBITDA | -$72.9M | -$30.5M | -$55.6M | -$55.5M | -$51.9M | -$48.9M | $23.9M | -$63.0M | -$34.0M | -$33.4M | -$18.7M | $5.6M |
| Operating cash flow | -$53.6M | -$59.6M | -$33.8M | -$44.7M | -$46.0M | -$63.0M | -$43.6M | -$46.5M | -$27.5M | -$33.4M | -$33.2M | -$34.5M |
| Free cash flow | -$54.5M | -$60.0M | -$33.8M | -$44.9M | -$46.3M | -$63.2M | -$43.7M | -$46.9M | -$27.5M | -$33.8M | -$33.6M | -$34.7M |
| Diluted shares | 204.0M | 200.2M | 180.3M | 167.7M | 164.0M | 162.6M | 161.7M | 132.6M | 129.5M | 129.3M | 109.9M | 107.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $368.0M | $544.6M | $602.1M | $196.2M | $208.5M | $243.1M |
| Short-term investments | $122.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $558.3M | $583.5M | $638.5M | $241.4M | $252.4M | $288.3M |
| Total liabilities | $104.8M | $71.8M | $112.3M | $109.0M | $105.2M | $108.7M |
| Shareholders' equity | $453.5M | $511.7M | $518.4M | $124.5M | $139.3M | $171.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology